Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2004;94:194-200
Published online before print December 11, 2003, doi: 10.1161/01.RES.0000111522.02730.56
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
94/2/194    most recent
01.RES.0000111522.02730.56v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ke, Y.
Right arrow Articles by Solaro, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ke, Y.
Right arrow Articles by Solaro, R. J.
Related Collections
Right arrow Contractile function
Right arrow Biochemistry and metabolism
Right arrow Cell signalling/signal transduction
Right arrow Heart failure - basic studies
(Circulation Research. 2004;94:194.)
© 2004 American Heart Association, Inc.


Molecular Medicine

Intracellular Localization and Functional Effects of P21-Activated Kinase-1 (Pak1) in Cardiac Myocytes

Yunbo Ke, Lynn Wang, W. Glen Pyle, Pieter P. de Tombe, R. John Solaro

From the Department of Physiology and Biophysics, Program in Cardiovascular Sciences, College of Medicine, University of Illinois at Chicago, Chicago, Ill.

Correspondence to R. John Solaro, PhD, Department of Physiology and Biophysics, M/C 901, College of Medicine, University of Illinois at Chicago, 835 S Wolcott Ave, Chicago, IL 60612-7342. E-mail SolaroRJ{at}uic.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
We investigated intracellular localization and substrate specificity of P21-activated kinase-1 (Pak1) in rat cardiac myocytes. Pak1 is a serine/threonine protein kinase that is activated by Rac1/Cdc42 and important in signaling of stress responses. Yet the localization and in vivo function of Pak1 in heart cells is poorly understood. Studies reported here indicate that Pak1 physically interacts with protein phosphatase 2a and localizes to the Z-disk, cell membrane, intercalated disc, and nuclear membrane of adult rat heart myocytes. We compared levels of phosphorylation of cardiac troponin I (cTnI) in control myocytes with phosphorylation of cTnI and myosin binding protein C (C-protein) in myocytes with increased Pak1 activity. The increase in activity was induced by infection of myocytes with a recombinant adenovirus (AdPak1) containing cDNA for a constitutively active Pak1. Control cells were infected with a virus (AdLacZ) containing LacZ. Basal levels of phosphorylation of cTnI and C-protein were relatively high in the myocytes infected with AdLacZ. However, phosphorylation of cTnI and C-protein in cells expressing constitutively active Pak1 was significantly reduced compared with those expressing LacZ. Measurement of Ca2+ tension relations in single myocytes demonstrated that this reduction in phosphorylation of cTnI and C-protein was associated with the predicted increase in sensitivity to Ca2+. Our data provide evidence for a novel pathway of phosphatase regulation in cardiac myocytes.


Key Words: heart failure • phosphatase • troponin


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
The thin-filament protein troponin I (cTnI) is a critical element in triggering and modulating the actin crossbridge reaction in heart muscle.1 cTnI is the inhibitory component of the Tn heterotrimer, which consists also of a Ca2+ binding protein (cTnC) and a tropomyosin binding protein (cTnT). Together with tropomyosin, the Tn complex confers Ca2+ regulation to myofilament activation. Phosphorylation of a unique N-terminal extension of cTnI by protein kinase A (PKA) enhances both Ca2+ release from cTnC2 and rate of crossbridge cycling.3 This reduction of myofilament response to Ca2+ as well as the enhanced crossbridge cycling indicates that cTnI phosphorylation may be of importance in enhancing cardiac relaxation during adrenergic stimulation. Studies on mice with cardiac-specific expression of slow skeletal TnI (which lacks PKA phosphorylation sites) in phospholamban+/+4 and phospholamban-/-5,6 mice provided evidence strongly supporting this hypothesis. The phosphorylation of cTnI may also be important in long-term regulation of cardiac function in the hypertrophic process and the transition to heart failure. Levels of phosphorylation of cTnI at the PKA sites appear low at end-stage heart failure.7,8 The consequent increase in myofilament Ca2+ sensitivity and slowing of crossbridge cycling may be of significance in altering power and dynamics of cardiac relaxation and in promoting the hypertrophic process.9 The mechanism of the decreased levels of phosphorylation at the cTnI PKA sites is likely to be attributable to downregulation of ß-adrenergic signal transduction in heart failure. Increased activity of phosphatases in heart failure may also contribute to decreased levels of cTnI phosphorylation.10

Pathways regulating the phosphorylation of cTnI at the PKA sites are relatively well understood; however, potential regulatory mechanisms for dephosphorylation of cTnI remain unclear. Type 2A phosphatase (PP2A) in heart is mainly responsible for dephosphorylation of both cTnI and phospholamban.11,12 Studies in neuronal cells have provided evidence that PP2A may interact with and be regulated by P21-activated kinase-1 (Pak1).13 Pak1 belongs to a highly conserved family of serine-threonine protein kinases regulated by Ras-related small G proteins, Cdc42, and Rac1.14 There is evidence that the development of compensated cardiac hypertrophy and the transition to decompensation and failure involve Rac1 and Pak1.15 Whether activation of Pak1 in cardiac myocytes is able to induce dephosphorylation of cTnI remains unknown. Moreover, it has been reported that in vitro Pak1 directly phosphorylates cTnI in the myofilament lattice.16

Experiments reported here were aimed at testing whether expression of active Pak1 in situ in cardiac myocytes alters phosphorylation and regulatory function of cTnI. Our results demonstrate relatively high levels of endogenous Pak1 in heart cells. By using adenoviral transfer of Pak1 into adult cardiac myocytes, we demonstrate that expression of active Pak1 reduces phosphorylation of cTnI and increases myofilament sensitivity to Ca2+. Our data indicate that rather than causing phosphorylation of cTnI, Pak1 promotes dephosphorylation of cTnI, most likely through the activation of PP2A.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Isolation and Culture of Ca2+-Tolerant Cardiac Ventricular Myocytes
Cardiac ventricular myocytes were isolated from the hearts of adult male rats (Harlan, Indianapolis, Ind), 2 to 3 months of age, using a collagenase perfusion method, as previously described.17 All experiments were performed according to institutional guidelines concerning the care and use of experimental animals. For cell culture, we allowed freshly isolated adult rat cardiac myocytes to settle onto cover slips (Fisherbrand No. 1D 12-545-83) in a 12-well tissue culture plate. The cover slips were precoated with mouse laminin at 10 µg/mL for 2 hours. The cells were first cultured for 2 hours in DMEM (Sigma D6421) plus 10% FBS for cell attachment. Then medium was replaced by DMEM without FBS. After we changed the medium to serum-free DMEM, the cells were cultured overnight.

AdPak1 Construction, Viral Amplification, and Plaque Assays
To prepare recombinant adenovirus that expresses constitutively active Pak1 (AdPak1), we used the polymerase chain reaction method to tag the human Pak1 cDNA with an HA epitope (YPYDVPDYA) at the N-terminal region and next to the translational initiation codon. Threonine 423 was mutated to glutamic acid in Pak1 cDNA to convert the Pak1 protein into a constitutively active form.18 The cDNA was cloned into a shuttle vector pAdCMV to obtain pAdCMVPak1. The AdPak1 was made by homologous recombination between pAdCMVPak1 and the viral backbone DNA DL7001.19 The lysate of virus amplified from a clone was used to infect cells cultured in 100-mm dishes, and 5 to 10 large dishes (150 mm) were infected with the lysate from 100-mm dishes. The cells were harvested 28 to 35 hours after infection. The lysates from the large dishes were applied at the top of a discontinuous CsCl gradient and centrifuged at 20 000g for 2 hours. The band containing virus was harvested and dialyzed against HBS buffer. Virus in the dialysis unit was used directly or mixed with storage buffer and stored at -80°C. The viral titer (plaque-forming units per milliliter) and multiplicity of infection (moi) were determined by standard techniques.20

Isolation, Activity, and Immunoprecipitation of Pak1 From Cardiac Myocytes
Freshly isolated rat cardiac myocytes were plated in 100-mm tissue culture plates at room temperature in Tyrode’s solution (pH 7.4) consisting of (in mmol/L) CaCl2 0.5, NaCl 132, KCl 4.8, NaH2PO4 1.2, MgSO4 1, HEPES 10, and glucose 11. The cells were infected with AdPak1 and incubated for {approx}8 hours. In control experiments, we found that the expression of Pak1 protein in cardiac myocytes began as early as 2 hours after infection with AdPak1. The expression reached a maximum at 6 to 8 hours and remained at this level for >15 hours. Cell proteins were extracted with lysis buffer (50 mmol/L Tris, pH 7.5; 150 mmol/L NaCl; 0.1% Nonidet P40; Complete Protease Inhibitor Cocktail Tablets [Roche Molecular Biochemicals]). The expressed Pak1 with an HA-tag was purified using an anti-HA affinity Matrix column (Roche Molecular Biochemicals, No. 1815016) following manufacturers instructions. The purified protein sample was dialyzed against 1 mmol/L HEPES buffer and lyophilized. Kinase activity of expressed Pak1 was determined in 50-µL reaction mixtures, which contained 0, 0.1, or 1 µg of the purified Pak1 protein, 10 µCi of [{gamma}-32P]ATP, and 5 µg of myelin basic protein in kinase assay buffer (50 mmol/L HEPES [pH 7.3], 10 mmol/L MgCl2, 2 mmol/L MnCl2, 1 mmol/L dithiothreitol, 0.05% Triton X-100). The mixture was incubated at 30°C for 30 minutes. Samples were resolved by SDS-PAGE on 12% gels and processed for autoradiography. We also immunoprecipitated expressed HAPak1 from infected cardiac myocytes and endogenous Pak1 from myocardium. The precipitated protein was resolved by SDS-PAGE and probed with PP2A antibody (Santa Cruz, No. sc-6110).

Labeling of Rat Myocytes With 32P
Experiments aimed at determining the level of protein phosphorylation in myocyte preparations were done using a protocol modified from that described by Fenzke et al.4 The freshly isolated adult rat cardiac myocytes were settled onto 35-mm tissue culture plates coated with mouse laminin, as described above. The cells were cultured for 2 hours in DMEM with 10% FBS. Viral infection (moi of 100) was carried out when serum-free medium was added to the cells. After freshly isolated cells were infected with AdPak1 or AdLacZ for 8 hours, in which the level of transgene expression was substantial, DMEM was replaced with Na-HEPES phosphate-free buffer (in mmol/L, CaCl2 1.0, KCl 4.8, MgSO4 1.2, NaCl 132, HEPES 10, Na pyruvate 2.5, and glucose 10; pH 7.4) with 0.5 mCi [32P] orthophosphate for 30 minutes at room temperature. The cells were then washed twice with the Na-HEPES solution with 1 mmol/L CaCl2. Two minutes after adding isoproterenol or vehicle, we added an equal volume of SDS-stop solution (in mmol/L, DTT 1, Tris-HCl 30, and EDTA 3, with 6% SDS, 15% glycerol, and a trace of bromophenol blue). Before analysis by SDS-PAGE, the samples were boiled for 10 minutes. Gel electrophoresis was performed using either a 12% or a linear 5% to 20% polyacrylamide gradient gel, as previously described.4 An aliquot of cells containing 50 µg protein, as determined using the Lowry method, was analyzed by SDS-PAGE, as previously described.4

Labeling of Proteins for Immunofluorescence and Western Blotting
For immunolabeling, cover slips containing adult rat cardiac myocytes were washed twice with PBS, and the cells were fixed with 2% paraformaldehyde. The cells were washed twice (5 minutes) with PBS containing 0.25% NH4Cl, 0.01% saponin, and 0.02% NaN3. The cells were then coated with PBS containing 0.5% BSA, 0.01% saponin, and 0.02% NaN3. The primary antibody was added in coating reagent and incubated for 30 minutes. The cells were washed three times in PBS containing 0.05% saponin and 0.02% NaN3, incubated in secondary antibody for 15 minutes in PBS containing 0.5% BSA, 0.01% saponin, and 0.02% NaN3, and then washed three times (for 5 minutes) with PBS containing 0.01% saponin and 0.02% NaN3. Anti-Pak1 ({alpha}-Pak) polyclonal antibody of rabbit origin was from Santa Cruz Biotechnology (No. sc-881). For immunofluorescence studies, we used a 1:50 dilution, and for Western blot analysis, a 1:200 dilution. The secondary antibody (1:200 dilution) was FITC-conjugated anti-rabbit IgG of goat origin (Sigma, No. F-9887). Rhodamine-conjugated phalloidin was purchased from Sigma (No. p 1951).

Images were acquired using a BioRad laser-scanning confocal microscope Radiance 2000 equipped with a x60 water immersion objective. A 488-nm and a 568-nm beam from an argon-krypton laser were used for excitation. Detection of the emissions from green and red fluorescence was through HQ515/30 and HQ590/70 filters, respectively. The collected images were processed using LaserPix version 4.0 (BioRad).

Tension-Ca2+ Relations in Skinned Cardiac Myocytes
Adult rat cardiac myocytes were infected with AdPAK1 or AdLacZ at moi of 100. After 15 hours in culture, isolated myocytes were washed for 15 minutes with ice-cold high-relax (HR) buffer at pH 7.0 containing, in mmol/L, EGTA 10, CaCl2 0.025, MOPS 20, KCl 50, MgCl2 6.8, phosphocreatine 12, and Na2ATP 5. HR also contained 5 mg/mL leupeptin, 12.5 mg/mL pepstatin, and 0.25 mmol/L PMSF, pH 7.0. At this stage, 1% Triton X-100 was added to HR to remove membranes. The mixture containing detergent-extracted cells was centrifuged at 10 000g for 10 minutes, and the pellet was washed in ice-cold HR. The suspension was centrifuged again, and the resulting pellet was resuspended in ice-cold HR buffer. The detergent-extracted cells were kept on ice up to a maximum of 8 hours until single myocytes were attached with silicone glue to micropipettes, as previously described.21 One micropipette was mounted to a force transducer (Cambridge model 403A), and the other to a high-speed motor (Cambridge model 308). Sarcomere length was set to 2.20 µm and monitored using custom-designed software (Labview, National Instruments); tension was computed from the cross-sectional area, as previously described.21 Ca2+ sensitivity was expressed as EC50 (Ca2+ concentration at half-maximal activation). The first and last contractions were at maximally activating Ca2+ to assess any functional decline. Only cells retaining >80% of their initial maximum contraction were kept for analysis.

Data Analysis
Data are presented as mean±SEM. The significance of differences between means was evaluated with 2-way ANOVA (for repeated measures, when appropriate). Values of P<0.05 were considered statistically significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Expression of Pak1 in Adult Rat Cardiac Myocytes Is Abundant and Localized to Z-Discs
To investigate subcellular localization of endogenous Pak1 in adult rat cardiac myocytes, we used immunofluorescence labeling and confocal microscopy. The saponin-permeabilized cardiac myocytes were probed with an antibody for Pak1. In control cells, rabbit and calf serum was used instead of Pak1 antibody. As displayed in Figure 1, left, Pak1 staining produced a striated pattern and demonstrated localization to cell and nuclear membranes. The result shown in Figure 1 is typical of >100 cells examined in this way. We observed no striations in control myocytes incubated with rabbit or calf serum without Pak1 antibody (data not shown). Western blot analysis for Pak1 detected a single band of 68 kDa in homogenates prepared from rat and mouse ventricle. A sarcomeric pattern was also observed when myocytes were stained with rhodamine-conjugated phalloidin in addition to Pak1 (Figure 1, right). The Pak1 signals are green, and actin signals demonstrated by the rhodamine-conjugated phalloidin staining are red. Yellow staining revealed a striated pattern of actin-Pak1colocalization and indicates a sarcomeric localization of the Pak1. This localization is additionally demonstrated by evidence displayed in Figure 2, which shows data similar to those in Figure 1, but at higher magnification. In Figure 2, the Pak1 signals (green on left) became yellow when superimposed with signals produced by rhodamine-conjugated phalloidin (red on right). Yellow staining forms stripes on each side of a relatively dark transverse band formed by the actin-free H-zone on the sarcomere. These results indicate that Pak1 localizes to the Z-disc. In Figure 3, we show immunofluorescence labeling of HAPak1 protein in a myocyte infected with AdPak1. In this case, sarcomeric localization of AdPak1 is not evident, indicating that the active Pak1 is situated in a cytosolic localization.



View larger version (148K):
[in this window]
[in a new window]
 
Figure 1. Expression of endogenous Pak1 in cultured adult rat cardiac myocytes. A, Adult rat cardiac myocytes were incubated with anti-Pak1 antibody at 1:50. B, Anti-pak1 antibody at 1:50 plus rhodamine-conjugated phalloidin at 1:1000. Myocytes were examined using confocal microscopy with a water immersion x60 objective.



View larger version (97K):
[in this window]
[in a new window]
 
Figure 2. Localization of Pak1 signals as striations in the middle of phalloidin bands. A, Adult rat cardiac myocytes were incubated with anti-Pak1 antibody at 1:50. B, Anti-pak1 antibody at 1:50 plus rhodamine-conjugated phalloidin at 1:1000. The experimental conditions were the same as described in Figure 1, except magnification is x2.



View larger version (68K):
[in this window]
[in a new window]
 
Figure 3. Expression of constitutively active HA-AdPak1 in adult cardiac myocytes. Myocytes in culture were infected with AdPak1 overnight, as described in Materials and Methods. The HAPak1 was detected by FITC-conjugated antibody (Roche Applied Science; No. 1 988 506). The nuclei were stained blue by DAPI (4',6'-diamidino-2-phenyindole).

Increased Pak1 Activity in Myocytes Is Associated With Dephosphorylation of Troponin I and Increased Myofilament Ca2+ Sensitivity
We tested whether the adenoviral transfer of HAPak1 DNA into cardiac myocytes resulted in expression of a constitutively active Pak1 with functionally significant effects. Figure 4 shows data demonstrating the expression level and activity of recombinant Pak1. Western blot analysis showed expression of HAPak1 protein in the cardiac myocytes (Figure 4A). The activity of the HAPak1 is demonstrated by data depicted in Figure 4B, which illustrate that the recombinant Pak1 protein isolated from infected myocytes was able to phosphorylate an exogenous substrate (myelin basic protein) in vitro. Pak1 was also able to phosphorylate cTnI in vitro (Data not shown). Data in Figure 4B agree with earlier reports on the ability of Pak1 to phosphorylate MBP and to autophosphorylate.22 To test whether the constitutively active Pak1 modifies the state of phosphorylation of myofilament proteins in situ, we compared 32P-orthophosphate incorporation into myofilament proteins in cardiac myocytes infected with AdLacZ or AdPak1. Lane 1 of Figure 5, which served as a standard, displays isoproterenol-induced incorporation of 32P into cTnI and myosin binding protein C in control myocytes that were not treated with the adenoviral constructs. Lane 2 shows the level of phosphorylation of cTnI and myosin binding protein C in cells infected with AdLacZ and in a basal state. However, as demonstrated in lane 3 of Figure 5, infection with AdPak1 significantly reduced both cTnI and myosin binding protein C phosphorylation. Incorporation of 32P into myosin light chain 2 and cTnT was essentially the same in all the cells.



View larger version (39K):
[in this window]
[in a new window]
 
Figure 4. Expression and activity of constitutively active HAPak1 in adult rat cardiac myocytes. Myocytes were infected with either AdLacZ or HA-AdPak1 in Tyrode’s solution, as described in Materials and Methods. A, Detection of the expressed Pak1 by antibody against HA tag. Lane 1, Myocytes infected with AdLacZ. Lane 2, Myocytes infected with AdPak1. B, Activity of Pak1 purified from infected myocytes demonstrated by phosphorylation of myelin basic protein. Lanes 1, 2, and 3 contain 0, 0.2, and 2 µg of Pak1 protein, respectively. The upper band results from Pak1 autophosphorylation, and the lower band from Pak1-induced phosphorylation of myelin basic protein. See Materials and Methods for details.



View larger version (71K):
[in this window]
[in a new window]
 
Figure 5. Active Pak1 inhibits phosphorylation of cTnI in adult rat cardiac myocytes. Myocytes were first infected with either AdPak1 or AdLacZ at moi of 100 and incubated in 32P to label the nucleotide pool. Myocyte proteins were subsequently separated by SDS-PAGE (12%) and subjected to autoradiography, as described in Materials and Methods. Lane 1, Positive control demonstrating phosphorylation of myosin binding protein C (MyB Prot C) and cTnI when myocytes without viral infection were treated with 1 µmol/L isoproterenol. Lane 2, Basal phosphorylation of cTnI, cTnT, ventricular myosin light chain 2 (MLC2v), and MyB Prot C in myocytes infected with AdLacZ. Lane 3, Demonstration of reduction in phosphorylation of cTnI and MyB Prot C in myocytes infected with AdPak1. The same results were obtained in 5 separate experiments.

To determine whether the dephosphorylation of cTnI translated into a functional effect, we measured the isometric tension as a function of Ca2+ in single myocytes that had been infected with the recombinant adenovirus expressing either Pak1 or LacZ before detergent extraction. Ample evidence indicates that phosphorylation of cTnI reduces the Ca2+ sensitivity of the myofilaments.1–3 Data summarized in Figure 6 show that Ca2+ sensitivity of tension was significantly higher in myofilaments from AdPak1-infected myocytes (EC50, 0.87±0.14 µmol/L) compared with AdLacZ controls (EC50, 1.43±0.08 µmol/L). Maximum developed isometric tension tended to be greater in myofilaments from AdPak1-infected myocytes (32.2±9.8 mN) compared with AdLacZ-infected myocytes (23.1±5.4 mN), but this trend did not reach statistical significance. The Hill coefficient (3.8±0.6 for AdLacZ and 3.9±0.8 for AdPak1-infected myocytes) was not different between treatment groups. Myofilaments of uninfected control myocytes (n=19) not subjected to culture demonstrated Ca2+ activation parameters (EC50, 1.40±0.03 µmol/L; maximum tension, 24.5±1.9 mN/mm2; and Hill n, 4.1±0.3) that were not significantly different from those of myocytes infected with AdLacZ.



View larger version (16K):
[in this window]
[in a new window]
 
Figure 6. Ca2+-dependent isometric tension development of detergent-extracted single myocytes cultured in the presence of AdLacZ or AdPak1. Myocytes were first infected with either AdPak1 or AdLacZ at moi of 100, and membranes were extracted in Triton X-100. Isometric tension of single myocytes infected with AdPak1 ({bullet}) and AdLacZ ({circ}) was measured as a function of Ca2+, as described in Materials and Methods. The half-maximally activating free Ca2+ (EC50) was significantly lower (P<0.05) in AdPak1-infected myocytes (0.87±0.14 µmol/L; n=4) than in AdLacZ myocytes (1.43±0.08 µmol/L; n=3). The maximum tension (Hill coefficient) was 32.2±9.8 mN/mm2 (3.9±0.8) for AdPak1 myocytes and 23.1±5.4 mN/mm2 (3.8±0.6) for AdLacZ controls (P>0.05). Data are presented as mean±SEM.

Results reported in Figure 6 demonstrate that the reduction in cTnI phosphorylation induced by Pak1 is associated with the expected functional effect of enhanced sensitivity to Ca2+. Inasmuch as PP2A is the major phosphatase dephosphorylating PKA sites on cTnI, we tested whether HAPak1 interacts with PP2A. We infected 911 cells in culture with AdPak1, purified the expressed protein by affinity chromatography, and probed for the copurification of PP2A with an antibody to the 36-kDa catalytic subunit of PP2A. As illustrated in Figure 7A, PP2A was copurified with HAPak1. As additional evidence that HAPak1 is able to activate PP2A, we probed an extract of cardiac myocytes infected with either AdLacZ or AdPak1 with an antibody that detects the phosphorylation of Y307 of PP2A catalytic subunit. Dephosphorylation of Y307 is associated with activation of PP2A. The results are depicted in Figure 7B. In myocytes infected with AdLacZ, we were able to detect a reaction of the antibody. However, in myocytes infected with AdPak1, we could not detect phosphorylation of Y307, which indicates activation of the catalytic subunit of PP2A. We also infected cardiac myocytes with AdPak1 and immunoprecipitated AdPak1 with the HA antibody. The immunoprecipitated proteins were then probed with an antibody to PP2A. As illustrated in Figure 7C, lane 1, PP2A copurified with HAPak1. Endogenous myocardial Pak1 also coimmunoprecipitated with PP2A, as illustrated by the data in Figure 7 (lanes 2 and 3). In this case, immunoprecipitation was carried out using an antibody to Pak1, and the resulting proteins were probed by Western blot analysis with antibodies to Pak1 and PP2A.



View larger version (52K):
[in this window]
[in a new window]
 
Figure 7. Demonstration of interactions between Pak1 and PP2A. A, Phosphatase PP2A associates with HAPak1, as detected by antibody for the 36-kDa catalytic subunit of PP2A. Lane 1, HAPak1 sample prepared by affinity chromatography and probed with antibody for PP2A catalytic subunit. Lane 2, Cell lysates probed with the same antibody. B, Pak1 inhibits phosphorylation of PP2A catalytic subunit at Tyr-307. Myocytes were infected with AdLacZ (lane 1) and AdPak1 (lane 2) at an moi of 100. The samples were resolved by SDS gel electrophoresis. Phosphorylation of Y307 was probed by a specific antibody (Santa Cruz, No. SC-12615). C, Lane 1, Adult rat myocytes were infected with AdHAPak1 at an moi of 100. The expressed Pak1 (constitutively active) was immunoprecipitated with anti-HA antibody. Lanes 2 and 3, Endogenous Pak1 and PP2A were coimmunoprecipitated from 2 samples of rat ventricle using Pak1 antibody. The samples were resolved by SDS gel electrophoresis. Pak1 and PP2A were detected by Western blot analysis.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
Data presented here are the first to demonstrate a significant functional effect of in situ Pak1 activation in cardiac myocytes. Our data are also novel in demonstrating dephosphorylation of cTnI and myosin binding protein C and enhanced myofilament Ca2+ sensitivity associated with increased Pak1 activity. These effects of Pak1 activation may be attributable to increased activity of phosphatase, most likely PP2A. Our results also alter thinking about the role of Pak1 in regulation of cardiac function in that they indicate that previously reported16 Ca2+-sensitizing effects of direct in vitro phosphorylation of cTnI by Pak3 on myofilament tension occur by a different mechanism in the case of in situ activation of Pak1. However, Pak3 has been identified to be expressed in rat and pig hearts.16 Pak2, a ubiquitously expressed member of the Pak family of proteins, may also be expressed in heart.14 The catalytic domains of Pak1, Pak2, and Pak3 share >93% homology, but N-terminal regions, believed to be of importance in cellular localization, may possess structural differences. Thus, we cannot rule out the possibility that functional effects of Pak isoforms involve a balance of direct phosphorylation and indirect activation of phosphatase activity. Moreover, it is also important to point out that both Rac1 and cdc42 have immediate downstream effectors other than Paks in cardiac myocytes.14,15,18

An important question is whether Pak1 is involved in signaling pathways in which dephosphorylation of cTnI is known to occur. It has been known for some time that cholinergic receptor agonists23 and adenosine receptor agonists24,25 induce an antiadrenergic effect and an associated dephosphorylation of substrates, including cTnI. Early studies indicated that the mechanism for this effect of adenosine or cholinergic agonists was a depression in adenylyl cyclase activity, resulting in depressed cAMP levels and depressed activation of PKA.23,25 However, subsequent experiments concluded that the effect was attributable to stimulation of protein phosphatases with little or no change in cAMP concentrations.24,26 Moreover, in the case of adenosine, antiadrenergic effects on intracellular Ca2+ and contraction of cardiac myocytes could be blocked by phosphatase inhibitors.27 Along these lines, Liu and Hofmann28 demonstrated that antiadrenergic effects mediated by adenosine A1 receptors in the perfused heart were associated with carboxy-methylation of the PP2A catalytic subunit, translocation of the holoenzyme, and dephosphorylation of both cTnI and phospholamban. Although these data strongly indicate that the antiadrenergic mechanism involves direct dephosphorylation of cTnI mediated by PP2A, another potential mechanism is an induced dephosphorylation and inhibition of the activity of the catalytic subunit of PKA itself.29

The signaling pathway by which PP2A becomes activated remains unclear, although recent data30 indicate that PP2A activation may be mediated through Gi-guanylyl cyclase p38 mitogen-activated protein kinase (MAPK) pathway. In cardiac myocytes in which Gi was blocked by pertussis toxin, dephosphorylation of cTnI at the PKA sites by adenosine did not occur.30,31 Similarly, inhibition of Gi by pertussis toxin prevented lysophosphatidic acid–induced cell spreading of fibroblasts.32 Zhang et al33 reported that coexpression of constitutively active forms of Rac and Cdc42, upstream regulators of Pak1 activity, in COS or HELA cells leads to the activation of p38. Moreover, Zhang et al33 demonstrated that Pak1 stimulated p38 activity and that a dominant-negative Pak1 depressed induction of p38 activation by both interleukin-1 and Rac/Cdc42. The conclusion drawn from these studies was that the initiation of the signaling cascade by Rac and Cdc42 is at the level of Pak1, which leads to the activation of p38 MAPK. Based on our present work and previously reported studies, we hypothesize that the signaling cascade activated in our experimental models consists of Gi stimulation of Rac or Cdc42, which in turn activate Pak1. Pak1 increases p38 MAPK activity, which stimulates PP2A-mediated dephosphorylation of cTnI. The importance of Pak1 in the regulation of phosphatase activity is evidenced by its highly conserved and ubiquitous nature. For example, PP2A in yeast is regulated by a phosphotyrosyl phosphatase activator, which is positioned downstream of Cla4P, the yeast homologue of Pak1.34

In addition to adenosine, there are other potential pathways for physiological and pathological signaling that promote the activity and expression levels of Pak1. These include bradykinin,35 lysophosphatidic acid,32 activators of the Rac1 pathway,15 and stressors such as osmotic shock.38 In agreement with our findings of a relatively high level of expression of Pak1 in adult rat cardiac myocytes, Clerk and Sugden36 first reported high basal levels of Pak1 in neonatal cardiac myocytes. Clerk and Sugden36 also demonstrated an increased activity of Pak1 when the cells were stressed by hyperosmotic shock. Hearts of mice expressing constitutively active Rac1 also demonstrated an activation of Pak1 compared with nontransgenic controls.

Activation of phosphatase PP2A by Pak1 has potential implications in heart failure. Pak1 is downstream of Rac1, and there is evidence that the constitutive activation of Rac1 in a transgenic mouse model leads to dilated cardiomyopathy. Sussman et al15 suggested that this phenotype was mediated through a loss of Pak1 regulation of the focal adhesions. Pak is known to interact with focal adhesion complexes at the cell membrane, where it is targeted to paxillin.37 With activation of Rac1 signaling, Sussman et al15 report a movement of Pak1 from a cytosolic to a particulate location. The deregulation of focal adhesions was proposed to result in loss of cell adhesion and normal systolic function that leads to a dilated cardiomyopathy. Our data indicate that consideration must also be given to the possibility that the activity of regulatory proteins such cTnI are also affected by altered Pak1 activation.


*    Acknowledgments
 
This work was supported by NIH Grants P01 HL 62426, R37 HL 22231, and RO1 HL 64035. Y.K. was supported by T32 HL 07692 and W.G.P. by an American Heart Association Post-Doctoral Fellowship.


*    Footnotes
 
Original received June 6, 2003; resubmission received October 1, 2003; revised resubmission received November 20, 2003; accepted November 25, 2003.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 
1. Solaro RJ, Wolska BM, Arteaga G, Martin AF, Buttrick P, de Tombe P. Modulation of thin filament activity in long and short term regulation of cardiac function. In: Solaro RJ, Moss RL, eds. Molecular Control Mechanisms in Striated Muscle Contraction. Boston, Mass: Kluwer; 2002: 291–327.

2. Robertson SP, Johnson JD, Holroyde MJ, Kranias E, Potter JD, Solaro RJ. The effect of TnI phosphorylation on static and kinetic Ca binding by cardiac TnC. J Biol Chem. 1982; 257: 260–263.[Free Full Text]

3. Kentish JC, McCloskey DT, Layland J, Palmer S, Leiden JM, Martin AF, Solaro RJ. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ Res. 2001; 88: 1059–1065.[Abstract/Free Full Text]

4. Fentzke RC, Buck SH, Patel JR, Lin H, Wolska BM, Stojanovic MO, Martin AF, Solaro RJ, Moss RL, Leiden JM. Impaired cardiomyocyte relaxation and diastolic function in transgenic mice expressing slow skeletal troponin I in the heart. J Physiol (Lond). 1999; 517: 143–157.[Abstract/Free Full Text]

5. Wolska BM, Arteaga GM, Pena JM, Phillips RM, Sahai S, de Tombe PP, Martin AF, Leiden JM, Kranias EG, Solaro RJ. Expression of slow skeletal troponin I in phospholamban knockout mice alters the relaxant effect of ß-adrenergic stimulation. Circ Res. 2002; 90: 882–888.[Abstract/Free Full Text]

6. Pi Y, Kemnitz KR, Zhang D, Kranias EG, Walker JW. Phosphorylation of troponin I controls cardiac twitch dynamics: evidence from phosphorylation site mutants expressed on a troponin I-null background in mice. Circ Res. 2002; 90: 649–656.[Abstract/Free Full Text]

7. Wolff MR, Buck SH, Stoker SE, Greaser ML, Mentzer RM. Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered ß-adrenergically medicated protein phosphorylation. J Clin Invest. 1996; 98: 167–176.[Medline] [Order article via Infotrieve]

8. van der Velden J, Papp Z, Zaremba R, Boontje NM, de Jong JW, Owen VJ, Burton PB, Goldmann P, Jaquet K, Stienen GJ. Increased Ca2+ sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res. 2003; 57: 37–47.[Abstract/Free Full Text]

9. de Tombe PP, Solaro RJ. Integration of cardiac myofilament activity and regulation with pathways signaling hypertrophy and failure. Ann Biomed Eng. 2000; 28: 991–1001.[CrossRef][Medline] [Order article via Infotrieve]

10. Neumann J, Eschenhagen T, Jones LR, Linck B, Schmitz W, Scholz H, Zimmermann N. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol. 1997; 29: 265–272.[CrossRef][Medline] [Order article via Infotrieve]

11. Mumby MC, Russell KL, Garrad LJ, Green DD. Cardiac contractile protein phosphatases: purification of two enzyme forms and their characterization with subunit-specific antibodies. J Biol Chem. 1987; 262: 6257–6265.[Abstract/Free Full Text]

12. MacDougall LK, Jones LR, Cohen P. Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur J Biochem. 1991; 196: 725–734.[Medline] [Order article via Infotrieve]

13. Westphal RS, Coffee RL Jr, Marotta A, Pelech SL, Wadzinski BE. Identification of kinase-phosphatase signaling modules composed of p70 S6 kinase-protein phosphatase 2A (PP2A) and p21-activated kinase-PP2A. J Biol Chem. 1999; 274: 687–692.[Abstract/Free Full Text]

14. Manser E, Lim L. Roles of PAK family kinases. Prog Mol Subcell Biol. 1999; 22: 115–133.[Medline] [Order article via Infotrieve]

15. Sussman MA, Welch S, Walker A, Klevitsky R, Hewett TE, Price RL, Schaefer E, Yager K. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest. 2000; 105: 875–886.[Medline] [Order article via Infotrieve]

16. Buscemi N, Foster DB, Neverova I, Van Eyk JE. p21-Activated kinase increases the calcium sensitivity of rat triton-skinned cardiac muscle fiber bundles via a mechanism potentially involving novel phosphorylation of troponin I. Circ Res. 2002; 91: 509–516.[Abstract/Free Full Text]

17. Wolska BM, Solaro RJ. Method for isolation of adult mouse cardiac myocytes for studies of contraction and microfluorimetry. Am J Physiol. 1996; 271: H1250–H1255.[Medline] [Order article via Infotrieve]

18. Manser E, Huang HY, Loo TH, Chen XQ, Dong JM, Leung T, Lim L. Expression of constitutively active alpha-PAK reveals effects of the kinase on actin and focal complexes. Mol Cell Biol. 1997; 17: 1129–1143.[Abstract]

19. Ranheim TS, Shisler J, Horton TM, Wold LJ, Gooding LR, Wold WS. Characterization of mutants within the gene for the adenovirus E3 14.7-kilodalton protein which prevents cytolysis by tumor necrosis factor. J Virol. 1993; 67: 2159–2167.[Abstract/Free Full Text]

20. Barr E, Carroll J, Kalynych AM, Tripathy SK, Kozarsky K, Wilson JM, Leiden JM. Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther. 1994; 1: 51–58.[Medline] [Order article via Infotrieve]

21. Fan D, Wannenburg T, de Tombe PP. Decreased myocyte tension development and calcium responsiveness in rat right ventricular pressure overload. Circulation. 1997; 95: 2312–2317.[Abstract/Free Full Text]

22. Zhao ZS, Manser E, Chen XQ, Chong C, Leung T, Lim L. A conserved negative regulatory region in {alpha}PAK: inhibition of PAK kinases reveals their morphological roles downstream of Cdc42 and Rac1. Mol Cell Biol. 1998; 18: 2153–2163.[Abstract/Free Full Text]

23. Lindemann JP, Watanabe AM. Mechanisms of adrenergic and cholinergic regulation of myocardial contractility. In: Sperelakis N, ed. Physiology and Pathophysiology of the Heart. 2nd ed. Boston, Mass: Kluwer; 1989: 423–452.

24. Gupta RC, Neumann J, Durant P, Watanabe AM. A1-adenosine receptor-mediated inhibition of isoproterenol-stimulated protein phosphorylation in ventricular myocytes: evidence against a cAMP-dependent effect. Circ Res. 1993; 72: 65–74.[Abstract/Free Full Text]

25. Dobson JG Jr. Mechanism of adenosine inhibition of catecholamine-induced response in heart. Circ Res. 1983; 53: 151–160.

26. Zhang JZ, MacLeod KM. Dissociation of negative inotropic effect of carbachol from changes in cAMP and PKA in perfused rat hearts. Am J Physiol. 1996; 271: H404–H409.[Medline] [Order article via Infotrieve]

27. Narayan P, Mentzer RM Jr, Lasley RD. Phosphatase inhibitor cantharidin blocks adenosine A1 receptor anti-adrenergic effect in rat cardiac myocytes. Am J Physiol Heart. 2000; 278: H1–H7.[Abstract/Free Full Text]

28. Liu Q, Hofmann PA. Antiadrenergic effects of adenosine A1 receptor-mediated protein phosphatase 2a activation in the heart. Am J Physiol. 2002; 283: H1314–H1321.

29. Liauw S, Steinberg RA. Dephosphorylation of catalytic subunit of cAMP-dependent protein kinase at Thr-197 by a cellular protein phosphatase and by purified protein phosphatase-2A. J Biol Chem. 1996; 271: 258–263.[Abstract/Free Full Text]

30. Liu Q, Hofmann PA. Modulation of protein phosphatase 2a by adenosine A1 receptors in cardiomyocytes: role for p38 MAPK. Am J Physiol. 2003; 285: H97–H103.[CrossRef]

31. Rosenthal RA, Lowenstein JM. Inhibition of phosphorylation of troponin I in rat heart by adenosine and 5'-chloro-5'-deoxyadenosine. Biochem Pharmacol. 1991; 42: 685–692.[CrossRef][Medline] [Order article via Infotrieve]

32. Ueda H, Morishita R, Yamauchi J, Itoh H, Kato K, Asano T. Regulation of Rac and Cdc42 pathways by Gi during lysophosphatidic acid-induced cell spreading. J Biol Chem. 2001; 276: 6846–6852.[Abstract/Free Full Text]

33. Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, Bokoch GM. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem. 1995; 270: 23934–23936.[Abstract/Free Full Text]

34. Van Hoof C, Janssens V, Dinishioutu A, Merlevede W, Goris J. Functional analysis of phosphotyrosyl phosphatase activator: molecular cloning of the homologues from Drosophila melanogaster and Saccaromyces cerevisiae. Biochemistry. 1998; 37: 12899–12908.[CrossRef][Medline] [Order article via Infotrieve]

35. Kozma R, Ahmed S, Best A, Lim L. The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. Mol Cell Biol. 1995; 15: 1942–1952.[Abstract]

36. Clerk A, Sugden PH. Activation of p21-activated protein kinase {alpha} ({alpha} PAK) by hyperosmotic shock in neonatal ventricular myocytes. FEBS Lett. 1997; 403: 23–25.[CrossRef][Medline] [Order article via Infotrieve]

37. Turner CE, Brown MC, Perrotta JA, Riedy MC, Nikolopoulos SN, McDonald AR, Bagrodia S, Thomas S, Leventhal PS. Paxillin LD4 motif binds PAK and PIX through a novel 95-kD ankyrin repeat, ARF-GAP protein: a role in cytoskeletal remodeling. J Cell Biol. 1999; 145: 851–863.[Abstract/Free Full Text]

38. Schwinger RH, Bohm M, Schmidt U, Karczewski P, Bavendiek U, Flesch M, Krause EG, Erdmann E. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation. 1995; 92: 3220–3228.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Circ Cardiovasc GenetHome page
D. Catalucci, P. Gallo, and G. Condorelli
MicroRNAs in Cardiovascular Biology and Heart Disease
Circ Cardiovasc Genet, August 1, 2009; 2(4): 402 - 408.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Marshall, N. Anilkumar, J. Layland, S. J. Walker, J. C. Kentish, A. M. Shah, and A. C. Cave
Protein phosphatase 2A contributes to the cardiac dysfunction induced by endotoxemia
Cardiovasc Res, April 1, 2009; 82(1): 67 - 76.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
K. A. Sheehan, Y. Ke, B. M. Wolska, and R. J. Solaro
Expression of active p21-activated kinase-1 induces Ca2+ flux modification with altered regulatory protein phosphorylation in cardiac myocytes
Am J Physiol Cell Physiol, January 1, 2009; 296(1): C47 - C58.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Thum, D. Catalucci, and J. Bauersachs
MicroRNAs: novel regulators in cardiac development and disease
Cardiovasc Res, September 1, 2008; 79(4): 562 - 570.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. V.G. Latronico, D. Catalucci, and G. Condorelli
Emerging Role of MicroRNAs in Cardiovascular Biology
Circ. Res., December 7, 2007; 101(12): 1225 - 1236.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. C. Wu and R. J. Solaro
Protein Kinase C {zeta}: A NOVEL REGULATOR OF BOTH PHOSPHORYLATION AND DE-PHOSPHORYLATION OF CARDIAC SARCOMERIC PROTEINS
J. Biol. Chem., October 19, 2007; 282(42): 30691 - 30698.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
K. A. Sheehan, Y. Ke, and R. J. Solaro
p21-Activated kinase-1 and its role in integrated regulation of cardiac contractility
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R963 - R973.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Ke, M. Lei, T. P. Collins, S. Rakovic, P. A.D. Mattick, M. Yamasaki, M. S. Brodie, D. A. Terrar, and R. J. Solaro
Regulation of L-Type Calcium Channel and Delayed Rectifier Potassium Channel Activity by p21-Activated Kinase-1 in Guinea Pig Sinoatrial Node Pacemaker Cells
Circ. Res., May 11, 2007; 100(9): 1317 - 1327.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Neulen, N. Blaudeck, S. Zittrich, D. Metzler, G. Pfitzer, and R. Stehle
Mn2+-dependent protein phosphatase 1 enhances protein kinase A-induced Ca2+ desensitisation in skinned murine myocardium
Cardiovasc Res, April 1, 2007; 74(1): 124 - 132.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. L. Engel, T. Kobayashi, B. Biesiadecki, J. Davis, S. Tikunova, S. Wu, and R. J. Solaro
Identification of a Region of Troponin I Important in Signaling Cross-bridge-dependent Activation of Cardiac Myofilaments
J. Biol. Chem., January 5, 2007; 282(1): 183 - 193.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. H. Brown, D. P. Del Re, and M. A. Sussman
The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits
Circ. Res., March 31, 2006; 98(6): 730 - 742.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Layland, R. J. Solaro, and A. M. Shah
Regulation of cardiac contractile function by troponin I phosphorylation
Cardiovasc Res, April 1, 2005; 66(1): 12 - 21.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J.E. Van Eyk
Lessons From Old and New Kinases
Circ. Res., February 6, 2004; 94(2): 135 - 137.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
94/2/194    most recent
01.RES.0000111522.02730.56v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ke, Y.
Right arrow Articles by Solaro, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ke, Y.
Right arrow Articles by Solaro, R. J.
Related Collections
Right arrow Contractile function
Right arrow Biochemistry and metabolism
Right arrow Cell signalling/signal transduction
Right arrow Heart failure - basic studies